

FERNANDO MAGRO, MD, PhD



Faculty of Medicine, Porto University
Pharmacology Department, 3rd floor
Dr. Plácido da Costa
4200-450 Porto, Portugal

A handwritten signature in blue ink that reads "FMAGRO" followed by a stylized flourish.

I. BIOGRAPHY

Prof. Fernando Magro is a consultant in Gastroenterology, Director of the Clinical Pharmacology Unit, medical prescription monitor, Pharmacy Committee consultant and coordinator of the Immunomodulator Study Group at the São João University Hospital in Porto, Portugal.

He's a founder, board member, and research head of the Portuguese IBD Study Group (GEDII).

He's an associate professor with tenure at the Faculty of Medicine of the University of Porto (FMUP), involved in two course units of the Masters in Medicine academic program and supervises or co-supervises Master and PhD students. Acting as a PhD supervisor, 9 students have already earned their degrees and 10 are currently under his supervision.

Internationally, he was recently appointed President-Elect of the European Crohn's and Colitis Organization (ECCO). He also serves as Associate Editor of the United European Gastroenterology Journal (UEGJ) and as a member of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD).

His degree in Medicine was awarded by FMUP in 1992 and he became a specialist in Gastroenterology in 1998. In 2007, he earned a doctorate degree in Pharmacology, became a specialist in Clinical Pharmacology by 2017 and in 2018 earned his tenure in "Experimental and Clinical Pharmacology and Toxicology" at FMUP.

Since 1995, his interest lies in Inflammatory Bowel Disease (IBD) and intestinal epithelial inflammation. With his colleagues at GEDII and FMUP, he has developed several studies correlating drug levels to new serum and fecal biomarkers.

Prof. Magro has published over 300 manuscripts and has more than 16,000 citations.

He has received several research grants and acted as the principal investigator in various projects - he's currently the PI of four studies.

He also acted as national coordinator for seven global clinical trials in IBD.

He has delivered more than 100 international talks and organized more than 50 national meetings.

His ultimate aim is to improve patients' quality of life through translational research and decision-making processes supported by the highest scientific evidence level.

II. AFFILIATIONS

- Faculty of Medicine, University of Porto, Portugal (FMUP)
- São João University Hospital Center, Porto, Portugal (CHUSJ)
- Specialty college of Clinical Pharmacology
- Portuguese IBD Study Group (GEDII)
- United European Gastroenterology Journal (UEGJ)
- International Organization for the Study of Inflammatory Bowel Disease (IOIBD)
- European Crohn's and Colitis Organization (ECCO)

III. CONFLICTS OF INTEREST

Prof. Magro served as a speaker and received honoraria from Merck Sharp & Dohme, Abbvie, Vifor, Falk, Hospira, and Biogen.